10128-ET-1 Development of Dual-Delivery Nanoparticles for Malignant Glioma: Tumor-Targeted and BBB-Penetrating siRNA/mRNA Therapeutics

Le résumé fourni par la source

Abstract Nucleic acid therapeutics, which allow for specific regulation of target genes, represent a promising strategy for cancer treatment. However, their clinical application to brain tumors remains limited, primarily due to the presence of the blood-brain barrier (BBB), a physiological obstacle that hinders drug delivery. In this study, we aimed to establish a novel dual drug delivery system (DDS) that enables both efficient brain penetration and tumor cell-specific targeting by employing a two-pronged approach using mRNA and siRNA. [1] Development of tumor-targeted siRNA-LNPs:We constructed lipid nanoparticles (LNPs) encapsulating VEGF-targeting siRNA, further modified with Fc-binding peptide lipids (FcBP) and anti-PD-L1 antibodies. These modifications significantly enhanced binding and growth-inhibitory effects against murine glioma cells (GL261). In a subcutaneous tumor model, the treatment resulted in a significant reduction in tumor volume and bioluminescence signals, demonstrating the therapeutic potential of this molecularly targeted DDS. [2] Brain delivery strategy using FUS and mRNA-LNPs: Luciferase mRNA-encapsulated LNPs were intravenously administered to normal mice, followed by focused ultrasound (FUS) irradiation in combination with microbubbles (MB), to transiently and selectively open the BBB. As a result, gene expression in the irradiated brain region was approximately 20-fold higher than in the non-irradiated side, and mRNA delivery into brain parenchymal cells was confirmed. This study highlights a hybrid DDS platform that combines physical BBB opening (via FUS) and molecular targeting (via antibody-modified LNPs), and proposes a novel nucleic acid-based therapeutic strategy for malignant gliomas, particularly those with recurrence or resistance to conventional therapies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.